{"schema_version":"secwatch.filing_event.v1","accession":"0001635088-26-000088","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2026-08-06T11:13:50+00:00","discovered_at":"2026-08-06T11:15:03.438163+00:00","generated_at":"2026-08-06T11:15:09.335579+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Roivant Q1 net loss $290.6M; cash $3.9B; brepocitinib launch on track for Sept 2026","bullets":["Net loss of $290.6M ($0.26 per share) vs $273.9M ($0.33) in prior-year quarter; revenue $1.4M.","Cash, equivalents, and marketable securities of $3.9B as of June 30, 2026; repurchased 7.3M shares for $208.7M in Q1.","Brepocitinib on track for DM launch by end of September 2026; Phase 3 CS (BEACON+) enrolled first patients; NIU data H2 2026.","Genevant received $950M from Moderna in July under $2.25B settlement; additional $1.3B contingent on §1498 appeal; new lawsuits against Pfizer/BioNTech in 21 jurisdictions.","R&D expenses rose to $202M (+$49.1M) and G&A to $165.5M (+$31.5M), partly due to Moderna settlement bonuses."],"urls":{"canonical":"https://secwatch.observer/filing/0001635088-26-000088","json":"https://secwatch.observer/filing/0001635088-26-000088.json","markdown":"https://secwatch.observer/filing/0001635088-26-000088.md","text":"https://secwatch.observer/filing/0001635088-26-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/0001635088-26-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/roiv-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:15:09.335579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}